Immatics N.V. Ordinary Shares
Market Cap
1.2B
Short interest (Jul 15)
3.7%
Net Short (Jul 27 ): 0.0%
Borrow Fee
1.03%
Available Shares
3M
Price Chart
Company Overview
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.